A099430 Stock Overview
Bio Plus Co., Ltd engages in the research and development, production, and sale of bio products in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Bio Plus Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩6,410.00 |
| 52 Week High | ₩9,090.00 |
| 52 Week Low | ₩6,070.00 |
| Beta | 0.71 |
| 1 Month Change | -3.03% |
| 3 Month Change | -6.56% |
| 1 Year Change | -4.61% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -20.99% |
Recent News & Updates
Shareholder Returns
| A099430 | KR Medical Equipment | KR Market | |
|---|---|---|---|
| 7D | -4.3% | -0.1% | -4.3% |
| 1Y | -4.6% | 18.0% | -1.0% |
Return vs Industry: A099430 underperformed the KR Medical Equipment industry which returned 18% over the past year.
Return vs Market: A099430 underperformed the KR Market which returned -1% over the past year.
Price Volatility
| A099430 volatility | |
|---|---|
| A099430 Average Weekly Movement | 3.1% |
| Medical Equipment Industry Average Movement | 6.3% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 12.0% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A099430 has not had significant price volatility in the past 3 months.
Volatility Over Time: A099430's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 84 | Hyun-Kyu Jung | www.ubioplus.co.kr |
Bio Plus Co., Ltd engages in the research and development, production, and sale of bio products in South Korea. It offers dermal fillers under the SkinPlus – Hyal, Bio+ Dew, HyalDew, DeneB Classic, Stilea, and 3-Senses brand names. The company also provides medical products, including InterBlock, an absorbable anti-adhesion barrier; Synofil, a synovial fluid replacement; and Blad-Care, a solution to temporarily improve cystitis symptoms.
Bio Plus Co., Ltd Fundamentals Summary
| A099430 fundamental statistics | |
|---|---|
| Market cap | ₩366.57b |
| Earnings (TTM) | ₩25.58b |
| Revenue (TTM) | ₩65.04b |
14.3x
P/E Ratio5.6x
P/S RatioIs A099430 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A099430 income statement (TTM) | |
|---|---|
| Revenue | ₩65.04b |
| Cost of Revenue | ₩25.52b |
| Gross Profit | ₩39.52b |
| Other Expenses | ₩13.94b |
| Earnings | ₩25.58b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 447.31 |
| Gross Margin | 60.76% |
| Net Profit Margin | 39.33% |
| Debt/Equity Ratio | 6.2% |
How did A099430 perform over the long term?
See historical performance and comparison